Menu
Precision medicine, also known as personalized medicine, aims to enhance healthcare quality by tailoring treatments to each person's unique genetic makeup, environment, and lifestyle. While a fully individualized approach to medicine is still a work in progress, the recognition that patient heterogeneity influences treatment effectiveness is not new1.
Historically, medicine has heavily relied on trial-and-error strategies for discovering, developing, and testing new treatments targeted at specific indications. This disease-centered approach resulted in predetermined standard therapies tailored to the “average patient.” While this one-size-fits-all approach has succeeded in many indications, it also carries significant drawbacks, particularly when dealing with complex diseases such as cancer or inherited disorders. In these cases, the risk of adverse side effects (e.g., toxicity) and reduced therapeutic response often result in poorer patient prognoses and quality of life1.
Precision medicine represents a patient-centric paradigm shift, acknowledging each individual's uniqueness while using real-world data and advanced statistics to guide the discovery-to-treatment process. For instance, pharmacogenomics requires us to look at each patient genomic data individually and in the context of others, enabling stratification into cohorts for predicting treatment responses2.
Success in precision medicine hinges on the ability to derive meaningful insights from large patient datasets. Fostering data diversity has the potential to further advance progress in this area1,3.
Recent technological advances have made precision medicine more accessible and impactful than ever before. Next-generation sequencing (NGS) has become more affordable, transforming it from a research-focused technology into a tangible clinical reality. This progress was further propelled by the widespread adoption of electronic health records (EHRs) and laboratory information management systems (LIMS), which not only facilitate population-scale research but also enable the use of clinical decision support tools for the delivery of targeted therapies to individual patients4.
The ability to identify genetic biomarkers and assess variant pathogenicity has grown significantly in the past decade. This has not only revolutionized patient diagnosis but also transformed drug development. A pivotal moment was the approval of imatinib by the FDA in 2001, the first small molecule targeted therapy for chronic myeloid leukemia (CML)5. By inhibiting the BCR-ABL fusion protein, imatinib was shown to effectively slow the progression of CML from chronic phase to blast crisis, making it the first of its kind.
This groundbreaking milestone paved the way for the approval of many other targeted therapies, such as gefitinib targeting EGFR alterations associated with NSCLC (2003) and trastuzumab for HER2-positive breast cancer (2006). The pace of new targeted drug approvals continues to accelerate year after year, heralding a promising era of precision medicine6.
Timeline of FDA-approved targeted therapies in cancer. Grey bubbles represent the relative number of approvals per year. Data source: Waarts et al 2022.
To achieve a truly personalized approach to medicine, the harmonization of translational and precision medicine is paramount. This coordination between early mechanism-based drug development and late-stage patient-centric approaches gives rise to an end-to-end biomarker-guided process, allowing us to optimize treatment strategies for patient cohorts right from the outset7.
Known as translational precision medicine, this emerging concept brings a fresh perspective to the translational gap, calling for a broader scope beyond a purely genetic-based definition of biomarkers and introducing a multimodal approach by taking into account a wider range of healthcare variables. To make this new concept a reality, significant technological progress is required in several key areas8:
[df_layout_shortcode id="280858"]
By addressing these critical areas of advancement, we can pave the way for a future where each patient receives personalized treatments tailored to her or his unique needs and characteristics. The pursuit of translational precision medicine promises to revolutionize healthcare, offering improved patient outcomes and transforming the landscape of medical research and development.
Powered by proprietary algorithms and enriched with data from 750+ institutions*, the SOPHiA DDM™ Platform accelerates advances in the field of precision medicine. Its core mission centers on empowering clinical researchers across healthcare and biopharma spheres alike.
To learn more about SOPHiA DDM™ BioPharma Solutions for biomarker-centric discovery, development, and application deployment, visit our page.
[df_layout_shortcode id="280847"]
* The number of institutions represents active customers who have generated revenue through the SOPHiA DDM™ Platform usage or Alamut™ Visual Plus licenses as of September 30, 2022.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
